07Mar 2025
Impact of Ductal Features on Abiraterone Efficacy in mPCa.

Impact of Ductal Features on Abiraterone Efficacy in mPCa.

The study analyzed 569 metastatic prostate cancer (mPCa) patients treated with abiraterone. Of these, 40 (7.0%) had ductal features. The study found no significant differences in PSA response, PSA progression-free survival (PSA-PFS), or radiographic progression-free survival (rPFS) between patients with and without ductal features in both the metastatic hormone-sensitive (mHSPC, N=165) and castration-resistant prostate cancer (mCRPC, N=404) cohorts.

  • #urology

Like

Save

Share